Cencora, Inc. (NYSE:COR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Cencora, Inc. (NYSE:COR) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $280.20.

Several equities analysts have recently weighed in on COR shares. Wells Fargo & Company raised their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target on the stock. Finally, StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the sale, the chief executive officer now directly owns 51,070 shares of the company’s stock, valued at $13,022,850. This represents a 8.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares of the company’s stock, valued at $5,241,249.24. The trade was a 9.03 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,675 shares of company stock worth $8,034,778. Company insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

Large investors have recently modified their holdings of the company. JFS Wealth Advisors LLC lifted its stake in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after purchasing an additional 46 shares during the last quarter. Banque Transatlantique SA purchased a new stake in shares of Cencora during the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora during the 4th quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC boosted its holdings in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after buying an additional 69 shares in the last quarter. Finally, Kentucky Trust Co purchased a new position in shares of Cencora in the 4th quarter valued at $33,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Price Performance

Shares of NYSE COR opened at $275.16 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm has a fifty day moving average of $253.81 and a 200 day moving average of $241.21. The firm has a market cap of $53.36 billion, a PE ratio of 39.14, a PEG ratio of 1.31 and a beta of 0.51. Cencora has a one year low of $214.77 and a one year high of $275.57.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.